| pubmed-article:9676281 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9676281 | lifeskim:mentions | umls-concept:C0237401 | lld:lifeskim |
| pubmed-article:9676281 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:9676281 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:9676281 | lifeskim:mentions | umls-concept:C0053139 | lld:lifeskim |
| pubmed-article:9676281 | lifeskim:mentions | umls-concept:C0077623 | lld:lifeskim |
| pubmed-article:9676281 | lifeskim:mentions | umls-concept:C0599473 | lld:lifeskim |
| pubmed-article:9676281 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9676281 | pubmed:dateCreated | 1998-8-11 | lld:pubmed |
| pubmed-article:9676281 | pubmed:abstractText | U-54494A, a racemic mixture of two enantiomers, is being developed in racemic form as an anticonvulsant drug candidate. A comparative pharmacokinetic study with intravenous and oral administration of the two individual enantiomers to the dog was conducted to evaluate the potential enantioselective pharmacokinetics of U-54494. Following i.v. administration, the (-)- and (+)-enantiomers showed no significant differences in plasma clearance (0.84 +/- 0.11 versus 0.86 +/- 0.06 l/hr/kg) and terminal elimination half-life (11.2 +/- 2.7 versus 8.0 +/- 2.6 hr) for the parent drug. However, the AUC of intact drug was two-fold lower with two-fold shorter elimination half-life following the oral administration for the (+)-enantiomer as compared to the (-)-enantiomer. Higher plasma levels of the four metabolites were also observed for the (+)-than for the (-)-enantiomer, particularly after oral administration. These results suggested that the (+)-enantiomer appeared to be more extensively metabolized by first-pass effect than the (-)-enantiomer after oral dosing, and as a result, oral bioavailability for the (+)-enantiomer is only one half of that for its antipode (12.0 +/- 1.5% versus 26 +/- 9%). | lld:pubmed |
| pubmed-article:9676281 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9676281 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676281 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9676281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676281 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9676281 | pubmed:issn | 1024-2430 | lld:pubmed |
| pubmed-article:9676281 | pubmed:author | pubmed-author:WilliamsM GMG | lld:pubmed |
| pubmed-article:9676281 | pubmed:author | pubmed-author:JonesB WBW | lld:pubmed |
| pubmed-article:9676281 | pubmed:author | pubmed-author:ZhongW ZWZ | lld:pubmed |
| pubmed-article:9676281 | pubmed:author | pubmed-author:SchuetteM RMR | lld:pubmed |
| pubmed-article:9676281 | pubmed:author | pubmed-author:VandegiessenT... | lld:pubmed |
| pubmed-article:9676281 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9676281 | pubmed:volume | 1 | lld:pubmed |
| pubmed-article:9676281 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9676281 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9676281 | pubmed:pagination | 89-96 | lld:pubmed |
| pubmed-article:9676281 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:meshHeading | pubmed-meshheading:9676281-... | lld:pubmed |
| pubmed-article:9676281 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:9676281 | pubmed:articleTitle | Pharmacokinetics of the individual enantiomers of cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzamide monohydrochloride (U-54494A) in the dog. | lld:pubmed |
| pubmed-article:9676281 | pubmed:affiliation | Upjohn Laboratories, Pharmacia & Upjohn, Inc., Kalamazoo, Michigan 49001, USA. wzhong@pwinet.upj.com | lld:pubmed |
| pubmed-article:9676281 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9676281 | pubmed:publicationType | Comparative Study | lld:pubmed |
